

Notification:	HUM 7807
<u>Category:</u>	HCPCS - Drugs & Biologicals
<u>Topic:</u>	Louisiana Medicaid: fam-trastuzumab deruxtecan – HCPCS code
	<u>J9358</u>
What is changing? /	We limit reimbursement of charges for HCPCS code J9358 to no more
<b>Change Description:</b>	than 1 administration every 3 weeks and no more than 1,600 units
	per 6 weeks for any of the following diagnoses:
	Brain metastases in HER2-overexpressing breast cancer
	Breast cancer
	HER2-overexpressing biliary tract cancer
	HER-2 overexpressing cervical cancer
	• HER2-overexpressing endometrial carcinoma
	HER2-overexpressing occult primary
	HER2-overexpressing ovarian cancer
	HER2-overexpressing pancreatic adenocarcinoma
	HER2-overexpressing salivary gland tumors
	HER2-overexpressing small bowel adenocarcinoma
	HER2-overexpressing urothelial carcinoma
	HER2-overexpressing vaginal cancer
	HER2-overexpressing vulvar cancer
Why is Humana making this change?	The above limitations were established by the FDA-approved package
/ Change Reason:	insert and prescribing information and the pharmaceutical
	compendia.
	Note: The limitations described above are based on maximum
	dosages established in milligrams. If any units are denied, the
	provider may dispute the decision through the appropriate process.
	The provider may submit information, including medical notes
	showing the patient's body weight, that substantiates the medical
	necessity of the additional units.
<u>Language:</u>	<u>English</u>
Impacted Products:	Medicaid- Louisiana